HC Wainwright Reaffirms Buy Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. Several other research analysts also recently commented on ATNM. Cantor Fitzgerald reaffirmed an overweight rating […]

Related Keywords

,Actinium Pharmaceuticals Company Profile ,Sanders Morris Harris ,News Ratings For Actinium Pharmaceuticals Daily ,Maxim Group ,Cantor Fitzgerald ,Actinium Pharmaceuticals Inc ,Creative Financial Designs Inc ,Actinium Pharmaceuticals ,Vanguard Group Inc ,Virtu Financial ,Actinium Pharmaceuticals Price Performance ,Analyst Recommendations For Actinium Pharmaceuticals ,Brandywine Global Investment Management ,Free Report ,Moderate Buy ,Get Free Report ,Global Investment Management ,Financial Designs ,Morris Harris ,Actinium Pharmaceuticals Daily ,